Sitagliptin + Metformin

Description

Introducing Sitagliptin + Metformin Tablets by PharmAlliance International Labs

At PharmAlliance International Labs, our mission is to redefine healthcare through innovation and excellence. We are proud to introduce our latest product, Sitagliptin + Metformin Tablets, designed to provide comprehensive management for type 2 diabetes mellitus.

Drug Classification: Optimizing Glycemic Control with Antidiabetic Agents

Sitagliptin and Metformin belong to distinct classes of antidiabetic agents:

Sitagliptin operates as a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhancing insulin secretion and reducing glucagon production.

Metformin, a biguanide, primarily targets hepatic glucose production and enhances peripheral glucose uptake.

Formulations: Tailored Solutions for Effective Treatment

Our Sitagliptin + Metformin Tablets are available in two formulations:

Sitagliptin 50mg / Metformin 500mg Tablets (14’s)

Sitagliptin 50mg / Metformin 1000mg Tablets (14’s)

These oral tablets offer convenience and ease of administration, packaged meticulously in blister packs containing 14 tablets each to ensure freshness and accessibility.

Indications: Managing Type 2 Diabetes Mellitus with Precision

Sitagliptin + Metformin Tablets are indicated for adults grappling with type 2 diabetes mellitus. This combination medication addresses multiple pathophysiological aspects of diabetes, including insulin secretion, insulin sensitivity, and hepatic glucose production, thereby improving glycemic control.

Usage: Enhancing Treatment Adherence and Efficacy

For optimal outcomes, Sitagliptin + Metformin Tablets should be taken orally with meals to minimize the risk of gastrointestinal side effects associated with Metformin. Adherence to the prescribed dosage and regimen outlined by healthcare providers is crucial, with regular blood glucose monitoring necessary to evaluate treatment efficacy and facilitate dosage adjustments as needed.

Dosage: Tailoring Treatment to Individual Needs

Dosage adjustments may be warranted based on the patient’s individual response to treatment and glycemic control goals. Typically, treatment commences with one tablet twice daily, with gradual titration guided by blood glucose levels and tolerance. Patients with renal impairment or concurrent comorbidities may require dosage adjustments under medical supervision.

Pharmacokinetics and Pharmacodynamics: Understanding Mechanisms of Action

Sitagliptin and Metformin exhibit rapid absorption post-oral administration, with peak plasma concentrations achieved within hours. Renal elimination predominates for both compounds, with Metformin predominantly excreted unchanged in the urine. Mechanistically, Sitagliptin inhibits DPP-4, prolonging the action of incretin hormones like GLP-1 and GIP, while Metformin curbs hepatic glucose production and enhances peripheral glucose uptake.

Side Effects: Prioritizing Patient Safety

While Sitagliptin + Metformin Tablets are generally well-tolerated, some individuals may experience gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal discomfort. Rare but severe side effects, including lactic acidosis, may occur, particularly in patients with renal impairment or predisposing factors. Promptly notify healthcare providers of any persistent or severe side effects for appropriate management.

Experience the efficacy and convenience of Sitagliptin + Metformin Tablets from PharmAlliance International Labs. Trust in our unwavering commitment to delivering quality medications that enhance the lives of patients with type 2 diabetes mellitus. For further details, visit our website or consult your healthcare provider today.